Free CE/CMEVideo

Mechanism Matters—How OTC Therapies Interrupt the Allergic Cascade

Release Date

June 30, 2026

Expiration Date

July 1, 2027

Credits

0.25 CME, COPE

Activity Overview

Allergic conjunctivitis is a common source of ocular discomfort in the United States, but it is frequently underdiagnosed and undertreated. In this 4-part Burst™ series, an expert panel discusses the etiology of seasonal and perennial allergic conjunctivitis and examines opportunities to individualize therapy, with a particular focus on over the counter (OTC) options.

Target Audience

The target audience for this program is ophthalmologists and optometrists who treat ocular allergy.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline characteristics of FDA-approved OTC therapeutic agents for allergic conjunctivitis

Course

Mechanism Matters—How OTC Therapies Interrupt the Allergic Cascade

Create Account